Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Chinese Academy of Medical Sciences, Fuwai Hospital | OTHER |
| Beijing Anzhen Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
This is a multi-omics research of Chinese cardiomyopathies patients, aiming to determine genetic risk factor and serial biomarkers of cardiomyopathies in diagnosis and prognosis.
Identification of novel biomarkers is needed to improve the diagnosis and prognosis of cardiomyopathy. Also,the marked variation of genes which is still unclear, may influence clinical outcomes is determined in part by genetic heterogeneity of the systemic response to pathological process.
Specific aim:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| cardiomyopathy | Patients are diagnosed as cardiomyopathy by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography. | ||
| disease control | Patients have similar symptoms with cardiomyopathy patients, and are further excluded by three cardiologists and recruited in Beijing Anzhen Hospital, recording the results of clinical lab and echocardiography. | ||
| healthy control | Healthy subjects are recruited in Beijing Anzhen Hospital, with negative results of echocardiography and clinical lab examination. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The primary objective of this study is to determine whether variation in genetic background or differentially expressed molecules influences clinical outcomes in cardiomyopathy. | The primary objective of this study is to determine whether variation in genetic background or molecules influences clinical outcomes in cardiomyopathy. Differentially expressed molecules are reported in multi-omics. | Five year |
| Measure | Description | Time Frame |
|---|---|---|
| Age for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting | |
| gender for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
Not provided
Inclusion Criteria:
Exclusion Criteria:
10.Chronic arrhythmia, unless there are studies documenting inclusion criteria prior to the onset of arrhythmia (except a patient with chronic arrhythmia, subsequently ablated, whose cardiomyopathy persists after two months is not to be excluded) 11.Malignancy 12.Pulmonary parenchymal or vascular disease (e.g., cystic fibrosis, cor pulmonale, or pulmonary hypertension) 13.Ischemic coronary vascular disease 14.Association with drugs (e.g., growth hormone, corticosteroids, cocaine) or other diseases known to cause hypertrophy
Not provided
Not provided
Not provided
Not provided
A diagnosis of cardiomyopaty is adjudicated by three cardiologists,according to current guidelines when there was clinical evidence of cardiomyopathy together with clinical symptoms of heart failure or echocardiography or imaging evidence.
Patients have smiliar symptoms and are suspected as cardiomyopathy and further excluded by imaging examnation.
age- and gender- mathced healthy controls are also recuitted in the hospital.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Jie Du, PhD | Contact | jiedubj@126.com | ||
| Yulin Li, PhD | Contact | lyllyl_1111@163.com |
| Name | Affiliation | Role |
|---|---|---|
| Jie Du, PhD | Beijing Anzhen Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Institute of heart, lung and blood vessel diseases | Recruiting | Beijing | Beijing Municipality | China |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 42381624 | Derived | Ma K, Yang J, Guo H, Li P, Li X, Dong Z, Zhang J, Zhang C, Yang P, Hua C, Zhu S, Li G, Zhang J, Ding N, Wang J, Ma XL, Lin Z, Dong J, Li Y, Li Y. Proteogenomics of Hypertrophic Cardiomyopathy Reveals Subtype-Specific Therapy. Circ Res. 2026 Jul 1. doi: 10.1161/CIRCRESAHA.126.328300. Online ahead of print. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
If a blood specimen is obtained, it will be separated and stored at -80 ℃ as plasma, viable cells, and extracted DNA. If a saliva specimen is obtained, it is stored for DNA. If a tissue specimen is obtained, it will be cut into small pieces and stored at liquid nitrogen.
| Height for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| Weight for each participant | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| Past medical history for each participant including disease history, surgical history, and family | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| Life style for each participant including smoking history and drinking, specify how many years | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| blood lipids(LDL,HDL,VLDL) | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| creatine | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| urea | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| blood glucose | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| D-dimer | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| hsCRP | These data is collected from the cases' medical record in an average of 1 month after the sample recruiting |
| All-cause death | The data is collected during follow-up visit at 1/3/5 years after discharge | One year/Three year/Five year |
| Re-hospitalization | Patients are hospitalized due to heart failure with decreasing left ventricular ejection fraction or worsen symptoms. The data is collected during follow-up visit at 1/3/5 years after discharge | One year/Three year/Five year |
| Heart transplantation | Patients are underwent heart transplantation due to "pump failure of heart".The data is collected during follow-up visit at 1/3 years after discharge | One year/Three year/Five year |
| Malignant arrythmia | Ventricular flutter and fibrillation, atrioventricular block,atrial fibrillation or other cardiac arrhythmia leads to syncope or should be Implantable Cardioverter-Defibrillator (ICD) implantation. | One year/Three year/Five year |
| Worsening heart failure | Worsen heart failure is defined as decreased ejection fraction(left ventricular ejection fraction decreased over 10%), left ventricular ejection fraction <45% and enlarged heart size measured by echocardiography and changing level of New York Heart Association (NYHA) Functional Classification.And patients who undergo left ventricular assist device (LVAD) will also be included.The data is collected during follow-up visit at 3/6/9/12/36/60 months after enrollment. | One year/Three year/Five year |
| RNA/micro RNA/long-noncoding RNA-sequencing data | The data is collected from lab in an average of 6 month after the sample recruiting |
| Proteomics on Liquid Chromatograph Mass Spectrometer/Mass Spectrometer of plasma sample | The data is collected from lab in an average of 6 month after the sample recruiting |
| Exon sequencing data | The data is collected from lab in an average of 6 month after the sample recruiting |
| Result of echocardiography-Ejection Fraction | The whole results of echocardiography report will be recorded. The indicate can reflect cardiac contraction function and be used for discriminating heart failure or non-heart failure as a main factor. | Three year |
| Result of echocardiography-Left Ventricular End Diastolic Diameter | The whole results of echocardiography report will be recorded. The indicate can reflect the size of heart and be used for determination of heart enlargement. | Three year |
| Result of echocardiography-E/A Ratio | The whole results of echocardiography report will be recorded. The indicate can reflect diastolic function. | Three year |
| Beijing Institute of heart, lung and blood vessel diseases | Recruiting | Beijing | Beijing Municipality | China |
|
| Shijie You | Enrolling by invitation | Beijing | China |
| ID | Term |
|---|---|
| D002311 | Cardiomyopathy, Dilated |
| D002312 | Cardiomyopathy, Hypertrophic |
| D019571 | Arrhythmogenic Right Ventricular Dysplasia |
| D002313 | Cardiomyopathy, Restrictive |
| ID | Term |
|---|---|
| D006332 | Cardiomegaly |
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D009202 | Cardiomyopathies |
| D000083083 | Laminopathies |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D001020 | Aortic Stenosis, Subvalvular |
| D001024 | Aortic Valve Stenosis |
| D000082862 | Aortic Valve Disease |
| D006349 | Heart Valve Diseases |
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
| D000013 | Congenital Abnormalities |
Not provided
Not provided